Dr. Martens (LON:DOCS) Stock Price Down 2.8% – What’s Next?

Dr. Martens plc (LON:DOCS)’s share price dropped 2.8% during mid-day trading on Thursday . The company traded as low as GBX 70.40 and last traded at GBX 71.08. Approximately 1,442,787 shares were traded during mid-day trading, a decline of 80% from the average daily volume of 7,223,208 shares. The stock had previously closed at GBX 73.10.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on DOCS shares. Royal Bank Of Canada reaffirmed a “sector perform” rating and set a GBX 100 price objective on shares of Dr. Martens in a research report on Tuesday, June 2nd. Berenberg Bank cut their target price on Dr. Martens from GBX 114 to GBX 110 and set a “buy” rating on the stock in a research report on Tuesday, May 19th. Two equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of GBX 105.

Dr. Martens Trading Down 2.8%

The company has a 50 day moving average of GBX 77.33 and a 200-day moving average of GBX 70.56. The stock has a market cap of £680.34 million, a price-to-earnings ratio of 29.62, a price-to-earnings-growth ratio of 6.40 and a beta of 0.26. The company has a debt-to-equity ratio of 108.85, a quick ratio of 1.13 and a current ratio of 2.61.

Insider Transactions at Dr. Martens

In other Dr. Martens news, insider Ije Nwokori acquired 118,516 shares of the stock in a transaction dated Thursday, June 25th. The stock was acquired at an average price of GBX 72 per share, with a total value of £85,331.52. Also, insider Giles Wilson acquired 68,313 shares of the company’s stock in a transaction that occurred on Thursday, June 25th. The stock was acquired at an average price of GBX 72 per share, with a total value of £49,185.36. Insiders have acquired 300,091 shares of company stock worth $22,061,656 over the last quarter. Insiders own 2.94% of the company’s stock.

Dr. Martens Company Profile

Founded in 1960, Dr. Martens is an iconic British brand with a global presence. “Docs” or “DMs” were originally
produced for their durability for workers, before being adopted by diverse youth subcultures and associated musical
movements. Today, Dr. Martens has transcended its roots while still celebrating its proud history. It operates in over
60 countries and employs over 3,650 people worldwide. Its operations are split across both Direct-to-Consumer and
wholesale channels, and in addition to its world-renowned “1460” boot its product segments span shoes including the
1461 shoe and Adrian loafer, sandals including the Zebzag mule, Kids ranges, as well as a growing line of bags and
accessories.

The Company successfully listed on the main market of the London Stock Exchange on 29 January 2021 (DOCS.L) and
is a constituent of the FTSE 250 index.